Orphan Drug Assessment and Pricing Summit

ICER

ICER hosted a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit included discussion of how methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system, to allow for broader insurance coverage for innovative new treatments.

Key Dates

Associated Materials

05/10/2017

05/10/2017

05/25/2017

Summit pre-reading


07/25/2017

07/25/2017 – 09/25/2017

Comments received during the 60-day public comment period on proposed framework changes.